The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin is Differentially Regulated
Overview
Affiliations
The HECA452 carbohydrate epitope, also termed cutaneous lymphocyte antigen, is known to bind to E-selectin and defines a human T cell subset preferentially found in inflamed skin. Activated T cells can express a functional form of the P-selectin glycoprotein ligand-1 (PSGL-1), the major ligand known for P-selectin. Here we show that PSGL-1 can exist in two forms, of which only one carries the HECA452 epitope and binds to E-selectin, while the other only binds to P-selectin. We have analyzed the glycoprotein ligands for E- and P-selectin on the mouse CD8+ T cell clone 4G3 at 4, 8, and 12 days after antigen-specific activation. Only at day 4 did the cells bind to E-selectin, whereas cells at all three activation stages bound to P-selectin. Expression of the HECA452 epitope correlated with E-selectin binding. In affinity isolation experiments, PSGL-1 was isolated as the major ligand by E-selectin-IgG and by P-selectin-IgG; however, PSGL-1 only bound to E-selectin at day 4, whereas it bound to P-selectin at all three activation stages. Immunoprecipitated PSGL-1 from cells at day 4, but not from cells at days 8 and 12, was recognized in immunoblots by monoclonal antibody HECA452. In immunoblots of total extracts of cells at day 4, HECA452 recognized a 240/140-kDa pair of protein bands as the major antigen. These bands could be completely removed by depletion of cell extracts with anti-PSGL-1 antibodies. Our data suggest that the carbohydrate requirements for binding of PSGL-1 to P-selectin differ from those necessary for binding to E-selectin. Furthermore, we conclude that the major glycoprotein carrier for the HECA452 epitope on activated 4G3 cells is PSGL-1.
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.
Pereira J, Arede L, Ferreira F, Matos A, Pereira D, Santos R Leukemia. 2024; 39(1):178-188.
PMID: 39455852 DOI: 10.1038/s41375-024-02446-w.
ODwyer M, Kirkham-McCarthy L, Cerreto M, Foa R, Natoni A Sci Rep. 2024; 14(1):1756.
PMID: 38243063 PMC: 10798956. DOI: 10.1038/s41598-024-52212-2.
Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression.
Donnelly C, Dykstra B, Mondal N, Huang J, Kaskow B, Griffin R Sci Rep. 2018; 8(1):420.
PMID: 29323143 PMC: 5765004. DOI: 10.1038/s41598-017-17981-z.
Effector and Regulatory T Cells Roll at High Shear Stress by Inducible Tether and Sling Formation.
Abadier M, Pramod A, McArdle S, Marki A, Fan Z, Gutierrez E Cell Rep. 2017; 21(13):3885-3899.
PMID: 29281835 PMC: 5786164. DOI: 10.1016/j.celrep.2017.11.099.
Natoni A, Smith T, Keane N, McEllistrim C, Connolly C, Jha A Leukemia. 2017; 31(12):2642-2651.
PMID: 28439107 PMC: 5729350. DOI: 10.1038/leu.2017.123.